| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/09/2009 | WO2009044554A1 Preparation and method of administering vaccine and iontophoresis device using the preparation |
| 04/09/2009 | WO2009044284A1 Antibodies specific for human hepcidin |
| 04/09/2009 | WO2009044272A2 Laser-based vaccine adjuvants |
| 04/09/2009 | WO2009044208A1 Protein |
| 04/09/2009 | WO2009044165A2 Molecular adjuvant |
| 04/09/2009 | WO2009044153A2 Inhibitors and uses |
| 04/09/2009 | WO2009043933A1 Il-23 antibodies |
| 04/09/2009 | WO2009043922A2 Extracellular targets for alzheimer's disease |
| 04/09/2009 | WO2009043900A1 Drug transfer based on coenzyme a and acyl carrier protein |
| 04/09/2009 | WO2009043191A2 Method for producing macro-porous materials |
| 04/09/2009 | WO2009043166A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/09/2009 | WO2009043165A1 Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| 04/09/2009 | WO2009043155A2 Distinct hiv-1 gag and env epitopes of hla alleles associated with differential susceptibility to hiv-1 infection |
| 04/09/2009 | WO2009043103A1 Therapeutic antibody purification method and method of use |
| 04/09/2009 | WO2009026465A3 Composition and methods of making and using influenza proteins |
| 04/09/2009 | WO2009023164A3 Induction of mucosal immunity |
| 04/09/2009 | WO2009013018A3 Compositions and methods for generating an immune response in a subject |
| 04/09/2009 | WO2009010290A3 Engineered anti-alpha v- integrin hybrid antibodies |
| 04/09/2009 | WO2009009591A4 Use of cells to facilitate targeted delivery of nanoparticle therapies |
| 04/09/2009 | WO2009009039A3 Compositions containing full-length l1r nucleic acid and endoplasmic reticulum targeting sequence |
| 04/09/2009 | WO2009004094A3 Compounds and methods for the treatment of renal disease |
| 04/09/2009 | WO2009003905A3 Prognostic method for the determination of the suitability of biopharmaceutical treatment |
| 04/09/2009 | WO2009003889A3 Immunogenic analogues of rankl |
| 04/09/2009 | WO2009000099A3 Methods of modifying antibodies, and modified antibodies with improved functional properties |
| 04/09/2009 | WO2008156778A3 Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
| 04/09/2009 | WO2008148879A3 Use of a substance to improve postoperative outcome after end-to-end reconstruction of peripheral nerves |
| 04/09/2009 | WO2008135259A3 Antibody molecule composition |
| 04/09/2009 | WO2008088902A8 Attenuation of the adaptive immune response |
| 04/09/2009 | WO2008082651A3 Dual-specific il-1a/ il-1b antibodies |
| 04/09/2009 | WO2008079464A3 Stable powder formulations of alum-adsorbed vaccines |
| 04/09/2009 | WO2008070666A3 Compositions and methods to treat cancer with cpg rich dna and cupredoxins |
| 04/09/2009 | WO2008049098A3 ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1 |
| 04/09/2009 | WO2008028031A3 Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel |
| 04/09/2009 | WO2008019062A3 Polypeptide derivatives of parathyroid hormone (pth) |
| 04/09/2009 | WO2007111875A3 Methods for diagnosing and treating kidney and colorectal cancer |
| 04/09/2009 | WO2007098297A3 Method for diagnosing and treating kidney cancer |
| 04/09/2009 | WO2007076200A3 Antagonists of hmgb1 and/or rage and methods of use thereof |
| 04/09/2009 | WO2007041171A3 Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
| 04/09/2009 | WO2007038623A3 Oral formulation for enteric disorders and/or rehydration |
| 04/09/2009 | WO2007024976A3 Virus coat protein/receptor chimeras and methods of use |
| 04/09/2009 | WO2006098901A3 Influenza hemagglutinin and neuraminidase variants |
| 04/09/2009 | WO2006089218A3 Methods and compositions for modulating angiogenesis |
| 04/09/2009 | WO2006085979A3 Soluble forms of hendra and nipah virus g glycoprotein |
| 04/09/2009 | WO2006085959A3 Fusion proteins comprising cd4 minimal modules and methods of use thereof |
| 04/09/2009 | WO2006084092A3 Antibodies to oncostatin m receptor |
| 04/09/2009 | WO2006073446A3 Peptide-mediated protein transduction into cells the hematopoietic lineage |
| 04/09/2009 | WO2006050166A3 Methods of preventing and treating rsv infections and related conditions |
| 04/09/2009 | WO2006046963A3 Generation of virus-like particles and use as panfilovirus vaccine |
| 04/09/2009 | WO2006044333A3 Methods and materials for the inhibition of transplant rejection |
| 04/09/2009 | WO2006039407A3 Validation of tssk family members and tsks as male contraceptive targets |
| 04/09/2009 | WO2006036878A3 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same |
| 04/09/2009 | WO2006033768A3 Hcv multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof |
| 04/09/2009 | WO2006031524A3 Early detection of hemangiosarcoma and angiosarcoma |
| 04/09/2009 | WO2006026275A3 Methods for inducing uterine contraction and compositions useful therefor |
| 04/09/2009 | WO2006014422A3 Polynucleotide encoding a trim-cyp polypeptide, compositions thereof, and methods of using same |
| 04/09/2009 | WO2005121175A3 Env polypeptide complexes and methods of use |
| 04/09/2009 | WO2005115457A3 Combined active and passive targeting of biologically active agents |
| 04/09/2009 | WO2005112998A3 Compositions and methods for preventing erythropoietin-associated hypertension |
| 04/09/2009 | WO2005086775A3 Lumen-exposed molecules and methods for targeted delivery |
| 04/09/2009 | WO2005081872A3 Methods and compositions comprising supramolecular constructs |
| 04/09/2009 | WO2005077103A3 Compositions and methods for modification and prevention of sars coronavirus infectivity |
| 04/09/2009 | WO2005077071A3 Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| 04/09/2009 | WO2005041865A3 Compounds and method for treating cancer |
| 04/09/2009 | WO2005027840A3 Combination approaches for generating immune responses |
| 04/09/2009 | WO2005027715A3 CRYSTALS AND STRUCTURES OF SARS-CoV MAIN PROTEASE |
| 04/09/2009 | WO2004103287A3 B-arrestin-2 modulation in the treatment of allergic asthma |
| 04/09/2009 | WO2004101511A3 Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases |
| 04/09/2009 | WO2004077021A3 Standardized evaluation of therapeutic efficacy based on cellular biomarkers |
| 04/09/2009 | US20090094715 Methods of use of antibodies with reduced immunogenicity or toxicity |
| 04/09/2009 | US20090094704 for determining bioactive intact PTH levels in serum, plasma, and/or cell culture media; have a novel recognition for amino acid residues extending beyond the first N-terminal PTH residue; have binding affinity and specificity for PTH that have mitigated cross-reactivity to large non (1-84) PTH fragments |
| 04/09/2009 | US20090093622 BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis |
| 04/09/2009 | US20090093617 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 04/09/2009 | US20090093428 Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis |
| 04/09/2009 | US20090093413 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/09/2009 | US20090093412 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/09/2009 | US20090093402 Albumin Fusion Proteins |
| 04/09/2009 | US20090093057 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 04/09/2009 | US20090093050 DNA Vaccine Enhancement with MHC Class II Activators |
| 04/09/2009 | US20090093002 Humanized antibody |
| 04/09/2009 | US20090092963 Method for combined parallel agent delivery and electroporation for cell structures an use thereof |
| 04/09/2009 | US20090092666 Vaccines with enhanced immune response and methods for their preparation |
| 04/09/2009 | US20090092652 Method for the inhibition of angiogenesis or cancer using protective antigen related molecules |
| 04/09/2009 | US20090092640 Increased T-cell tumor infiltration and eradication of metastases by mutant LIGHT |
| 04/09/2009 | US20090092639 Immunogenic composition |
| 04/09/2009 | US20090092638 Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use |
| 04/09/2009 | US20090092637 Medicaments and methods to treat autoimmune disease and cancer |
| 04/09/2009 | US20090092636 Multivalent pcv2 immunogenic compositions and methods of producing such compositions |
| 04/09/2009 | US20090092635 Heterologous prime-boost immunization regimen |
| 04/09/2009 | US20090092634 Chicken Virus Vaccine and Diagnostic |
| 04/09/2009 | US20090092633 Polyamino acid for use as adjuvant |
| 04/09/2009 | US20090092632 Methods for preparing complex multivalent immunogenic conjugates |
| 04/09/2009 | US20090092631 Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response |
| 04/09/2009 | US20090092630 Chimeric recombinant antigens of toxoplasma gondii |
| 04/09/2009 | US20090092629 Vaccine for nontypeable haemophilus influenzae infection |
| 04/09/2009 | US20090092628 Conserved-element vaccines and methods for designing conserved-element vaccines |
| 04/09/2009 | US20090092627 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 04/09/2009 | US20090092626 Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1 |
| 04/09/2009 | US20090092625 administering hematopoietic cells to increase blood platelet; for patient receiving cancer chemotherapy or radiation therapy, or immunosuppressants; treating blood disorders anemia, myeloma, non-Hodgkin's lymphoma, Hodgkins lymphoma and leukaemia |
| 04/09/2009 | US20090092624 Antiinfective Flavononol Compounds and Methods of Use Thereof |
| 04/09/2009 | US20090092623 Promoter |